Gastrointestinal Metastases from Breast Cancer, a Diagnostic Dilemma

Abstract

**Background:** Those diagnosed with breast cancer are surviving longer due to advances in treatment. Metastatic spread to any site may not occur for years after primary surgical and systemic treatments and will most likely be diagnosed by General Practitioners. Breast cancer rarely metastasizes to the gastrointestinal tract. Due to this, scarce literature is available; mostly case-reports or small case-series. Our aim is to review two recent cases and to highlight our institution’s data. General Practitioners need to remember the potential gastrointestinal metastatic spread of breast cancer.

**Methods:** Two recent cases of breast cancer metastatic to the gastrointestinal tract are presented. Medical charts of 1169 women with metastatic breast cancer were reviewed from the Mayo Clinic, Rochester, MN. Site of metastases included the peritoneum and the gastrointestinal tract. Basic demographic information, tumor characteristics, timing of primary diagnosis and relapse, and gastrointestinal symptoms were recorded. Descriptive statistics were calculated.

**Results:** Of 1169 patients seen, there were 32 cases of breast cancer metastasizing to the gastrointestinal tract and peritoneum. Breast cancer histology included 47% lobular, 31% ductal, 13% mixed, and 9% unknown. Most common sites of metastasis were peritoneum at 46%, followed by stomach (17%), colon (15%), and small bowel (15%). Receptor status was ER+ in 91%, PR+ in 62.5%, and HER2- in 90%. The most common presentation was nausea/vomiting, followed by stool changes, distension without nausea/vomiting or obstruction, and other symptoms which included weight loss, anemia, ascites, early satiety, and dysphagia. Approximately one-third had an obstruction. Four patients were asymptomatic and their metastases were found incidentally or on routine scanning. Average time from original breast cancer diagnosis to gastrointestinal metastasis was 6.7 years.

**Conclusion:** Although breast cancer will infrequently spread to the gastrointestinal tract, it should be remembered when patients with a history of breast malignancy have gastrointestinal complaints. General Practitioners who are following breast cancer patients after treatment should keep metastases in mind when considering the differential diagnosis.

**Keywords:** Breast cancer; Metastases; Gastrointestinal; Progesterone.

Introduction

Every year, approximately 225,000 women are diagnosed with breast cancer and another 40,000 die from the disease in the US. About 75% of all metastases will occur within the first 5 years after diagnosis of early-stage disease. This has been found to be especially true for hormone receptor-negative disease. Unfortunately, metastases can occur beyond that time, sometimes up to 30 years later, which is more common in hormone-positive disease [1,2].

Breast cancer will typically metastasize to lymph nodes, bone, lungs, liver, and brain. Most commonly, metastatic spread of any cancer type to the gastrointestinal tract is considered an uncommon phenomenon. One study of approximately 2500 cases, found only 21 patients (<1%) with metastasis to the gastrointestinal tract [3]. Of secondary tumors to the gastrointestinal tract, breast is second only to melanoma [4]. In one study that looked specifically at the colon and rectum, the leading source of metastases was breast, with melanoma second [5]. In an autopsy study performed on 707 cases of metastatic breast cancer, the stomach was involved in 10% of cases, small intestine in 9%, and large intestine in 8%, with the peritoneum involved in 25% of cases. Overall, the gastrointestinal tract was involved in 16% of cases [6].

Histological studies have found that lobular carcinoma metastasized to the same metastatic sites as ductal carcinoma; however lobular carcinoma frequently metastasized to unusual sites like the gastrointestinal tract, peritoneum, and adnexa [8-12]. In one of the earliest papers on the subject, all of the metastases to the stomach were infiltrating lobular cancer, and other papers had between 75-97% lobular histotype [13-16].
Borst and Ingold [3] study, which looked at patterns of metastasis between lobular and ductal carcinoma, invasive lobular carcinoma only accounted for 14% of the cases, but significantly metastasized to the gastrointestinal tract compared to invasive ductal carcinoma (4.5% vs. 0.2%), with small bowel being the most common location. Different metastatic patterns were also shown in Jain et al. where in infiltrating lobular carcinoma more commonly went to the peritoneum, as well as bone marrow [17].

Gastrointestinal metastases of breast cancer are rather uncommon occurrences, and are therefore not well-described in the literature, existing mostly in the form of case reports and series. Additionally, metastasis can occur beyond the time a patient has regular follow-up with an Oncologist. The purpose of this study is to bring to the attention of a General Practitioner the current thoughts and statistics on the gastrointestinal metastases of breast cancer and highlight data from patients who sought care at The Mayo Clinic from 2000-2013.

**Materials and Methods**

Approval for this study was granted by the Mayo Clinic Institutional Review Board and clinical records of primary breast cancer metastasizing to the gastrointestinal tract were reviewed retrospectively. Each of the patients was evaluated by a physician in the Medical Oncology department at the Mayo Clinic, Rochester from 2000 until February 2013. Most pathology reports from referrals were reviewed by Mayo, however some pathology reports were not able to be viewed due to either timing from original diagnosis or lack of original records. Those diagnoses were based on physician chart documentation. Charts were identified from Mayo’s Tumor Registry of patients who were either diagnosed with gastrointestinal metastases from primary breast cancer or referred to Mayo from an outside hospital for further treatment recommendations of gastrointestinal metastases. Demographic information included dates of primary diagnosis and relapses; sites of relapse, including initial, gastrointestinal, and all; presenting gastrointestinal symptom; and date of death. The site of metastases included the peritoneum and the gastrointestinal tract from the esophagus to anus. The only exclusion criterion was male gender.

The following two cases are illustrative of the diagnostic challenges

i. 1– 74 year-old female with a history of breast cancer at the age of 32 treated with mastectomy and radiation, pathology unknown. At age 64, the patient developed Contralateral DCIS, ER/PR+, treated with mastectomy and Anastrozole. At age 70, metastatic spread to lymph nodes, ER/PR+ and HER2- was found. Fulvestrant and Denosumab were initiated after complete staging also found bone metastases. Two years later, she was found to be anemic and colonoscopy revealed small polypoid lesions (she had prior history of adenomatous polyps) with breast cancer visible in colonic crypts, ER+/PR-/HER2- (Figure 1). CEA was elevated at 220 (normal value <5). A CA 27.29 breast cancer associated marker was normal at 18 (normal up to 28). She was treated with Exemestane and Denosumab, but unfortunately succumbed to disease ten months after the diagnosis of gastrointestinal metastases.

Figure 1: Pathology slides from case #1, showing intact crypts with complete replacement of the lamina propria by tumor.

ii. 2 – The second case involved a patient who was diagnosed with ER/PR+ breast cancer at the age of 51. She was treated with lumpectomy and Adriamycin/Cyclophosphamide chemotherapy followed by radiation and adjuvant Tamoxifen. A few years later, at the age of 55 during a diverticular surgery, she had a focal area of adenocarcinoma removed from her ovary. Pathology report never conclusively distinguished it as ovarian or breast primary. Tumor markers remained negative over many years as did CT scans. She was followed with surveillance without any systemic therapy. At the age of 68, she developed persistent nausea and vomiting with a gradual 50-pound weight loss. CT abdomen showed a
malignant process causing obstruction. She underwent a right colon resection with hemicolectomy. Tumor pathology was consistent with breast tissue and was ER+ and PR/HER2+. Letrozole was then prescribed adjuvantly. The patient is alive and well three years out from diagnosis of gastrointestinal metastases.

Results

Within the Mayo Clinic Tumor Registry, over 1,150 patients had the diagnosis of breast cancer with metastases from 2000 to early 2013. In all, 32 patients had spread to the either the peritoneum or the gastrointestinal tract itself. Histology at original diagnosis included 15 lobular, 10 ductal, 4 mixed, and 3 unknown.

Table 1 shows a breakdown of each site of metastases by histologic type. In all, there were 41 gastrointestinal sites of relapse in the 32 patients. Eight patients had multiple sites of gastrointestinal metastases: 7 had two sites of metastases and 1 had three sites. The most common site of metastases was the peritoneum (19), followed by stomach (7), colon (6) and small bowel (6). Lobular breast cancer was the most common known histological type in the 32 patients. Of the 41 sites of metastases, 36 had known histology: 66% (24/36) were either lobular or mixed, while 44% (16/36) were either ductal or mixed.

Table 1: Site of metastases and histological type.

<table>
<thead>
<tr>
<th></th>
<th>Lobular (20)</th>
<th>Ductal (12)</th>
<th>Mixed (4)</th>
<th>Unknown (5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peritoneum (19)</td>
<td>10</td>
<td>7</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Esophagus (1)</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Stomach (7)</td>
<td>4</td>
<td>1</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Small Bowel (1)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Duodenum (2)</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Jejunum (1)</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Ileum (2)</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Colon (6)</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Rectum (2)</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Table 2 shows the receptor status of the 32 patients. The estrogen hormone receptor was known to be positive in 91% of patients. Progesterone receptor positivity was a little less common at 63% of patients. HER2 receptor status was only known in 21 patients, but was negative in 90% of patients.

Table 2: Breast cancer receptor status of patients with GI metastases.

<table>
<thead>
<tr>
<th></th>
<th>+</th>
<th>-</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estrogen</td>
<td>29</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Progesterone</td>
<td>20</td>
<td>9</td>
<td>3</td>
</tr>
<tr>
<td>Her2</td>
<td>2</td>
<td>19</td>
<td>11</td>
</tr>
</tbody>
</table>

The average age at the diagnosis of breast cancer was 56.6 years. Twenty-four of 32 patients had the gastrointestinal tract as the first site of metastatic spread. Nineteen patients had sites of spread to other parts of the body in addition to just the gastrointestinal tract. Nine patients were diagnosed with primary breast cancer after presenting with gastrointestinal metastases. The time from original breast cancer diagnosis to gastrointestinal metastases was 6.7 years. Only 13 patients had a known date of death, which led to an average survival of 2.2 years from gastrointestinal metastases in those patients. (Data not shown)

Table 3 shows presenting symptoms of patients with gastrointestinal breast cancer metastases. The most common presentation was nausea/vomiting at 56% (18/32). Of those 18 patients, 61% had chart documentation of an obstruction: 8 bowel and 3 gastric. Next, 28% had changes in stool, including different caliber, color or frequency. Distension without nausea/vomiting or obstruction was seen in 25%. Other symptoms included weight loss, anemia, ascites, early satiety, and dysphasia. Four patients had no symptoms and their metastases were found incidentally or on routine scanning.

Table 3: Presenting symptoms of patients with GI metastases.

<table>
<thead>
<tr>
<th>Presenting Symptoms</th>
<th># of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal Pain</td>
<td>7 (not including obstruction)</td>
</tr>
<tr>
<td>Stool Change</td>
<td>9</td>
</tr>
<tr>
<td>Weight Loss</td>
<td>6</td>
</tr>
<tr>
<td>Distension</td>
<td>8</td>
</tr>
<tr>
<td>Dysphasia</td>
<td>1</td>
</tr>
<tr>
<td>Ascites</td>
<td>3</td>
</tr>
<tr>
<td>Early Satiety</td>
<td>2</td>
</tr>
<tr>
<td>Anemia</td>
<td>2</td>
</tr>
<tr>
<td>Obstruction</td>
<td>11 (8 bowel, 3 gastric)</td>
</tr>
<tr>
<td>Asymptomatic</td>
<td>4</td>
</tr>
</tbody>
</table>

Discussion

Approximately 25% of all metastases from breast cancer occur beyond the first 5 years of the diagnosis of early-stage disease [1]. Even though it is infrequent, it is important for physicians, especially primary care providers who follow oncology patients after treatment is rendered, to keep in mind that gastrointestinal complaints can occur years later and be the first signs of metastatic spread in patients with a history of breast cancer [18-21]. This is especially true for patients with lobular carcinoma due to its increased frequency of gastrointestinal metastases compared to ductal-type [3,22]. Although the chances of having a primary colon cancer or other gastrointestinal process are higher, the possibility of recurrent, metastatic breast cancer still exists.

A recent paper also analyzed the sites of gastrointestinal breast cancer metastases [23]. They reviewed the existing literature, but only had 5 cases from their institution. In their review of literature, the most common site of gastrointestinal metastasis of breast cancer was the stomach (60%), followed by esophagus (12%), colon (11%), and small intestine (8%).
Symptoms arising from stricture obstruction were most common. Our single institution review is one of the few papers to include the peritoneum as a site of metastases. It is important since it is the mucosal surface of the gastrointestinal tract. It is interesting to note that the most common site of gastrointestinal metastases in this series was the peritoneum with 59% (19/32) of patients. The stomach (17%), colon (15%), and small bowel (15%) followed.

This study reaffirms the fact that lobular carcinoma being less common than ductal; it more frequently metastasizes to the GI tract [11,12,20,24]. Interestingly, 5–15% of patients have metastases when they are diagnosed with breast cancer [25]. In our series, 9/28% primary breast cancers were also diagnosed because of gastrointestinal metastases. This study is also unique because it recorded receptor status. A vast majority were estrogen receptor positive, as expected in lobular carcinoma. Approximately two-thirds were progesterone positive and most with known Her2 receptors were negative.

The time from original breast cancer diagnosis to GI metastasis was 6.7 years in this series. Other studies ranged from 4.4 to 9.5 years [11,20,24,26]. Because breast cancer patients follow with an oncologist only sporadically after diagnosis and first treatment, it is important for these patients to follow with a general practitioner, such as an Internist or Family Physician. These are the physicians who will most likely see the patient if vague gastrointestinal symptoms occur months to years after their diagnosis and treatment. Tumor markers such as CEA and CA27.29 may be informative for symptomatic patients with a distant history of breast cancer. However, they are not totally reliable [27]. CT and PET/CT scans can be very difficult to diagnose small volume disease and are likely only to be diagnostic for patients with obstruction. Our second case emphasizes that routine surveillance with scans in an asymptomatic patient are unwarranted. For all primary care providers, it is important to remember that patients with a history of breast cancer, vague gastrointestinal symptoms, most commonly nausea/vomiting, can be the sentinel clue to gastrointestinal metastases.

Acknowledgements

We would like to thank Jeremy Vold (Mayo Clinic Rochester Tumor Registry), Larry Prokop (Mayo Clinic Rochester Library), and Rob Vierkant (statistician) for their help in this review and analysis. Vicki Shea, research secretary, helped with formatting this report.

References


